Exploring Pembrolizumab‐Induced IM3OS in a Patient With Bladder Cancer
ABSTRACT Pembrolizumab, an immune checkpoint inhibitor (ICI), has transformed cancer treatment across various malignancies, including metastatic urothelial cancer. As the use of pembrolizumab becomes increasingly widespread, understanding its potential adverse effects is essential. Here, we present...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Wiley
2026-02-01
|
| Colección: | Pharmacology Research & Perspectives |
| Acceso en línea: | https://doi.org/10.1002/prp2.70212 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|